Cargando…
NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure
N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is a well‐established biomarker in heart failure (HF) but controversially discussed as a potential surrogate marker in HF trials. We analyzed the NT‐proBNP/mortality relationship in real‐world data (RWD) of 108,330 HF patients from the IBM Watson...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360001/ https://www.ncbi.nlm.nih.gov/pubmed/33630302 http://dx.doi.org/10.1002/cpt.2222 |
_version_ | 1783737653708980224 |
---|---|
author | Schmitt, Walter Rühs, Hauke Burghaus, Rolf Diedrich, Christian Duwal, Sulav Eissing, Thomas Garmann, Dirk Meyer, Michaela Ploeger, Bart Lippert, Jörg |
author_facet | Schmitt, Walter Rühs, Hauke Burghaus, Rolf Diedrich, Christian Duwal, Sulav Eissing, Thomas Garmann, Dirk Meyer, Michaela Ploeger, Bart Lippert, Jörg |
author_sort | Schmitt, Walter |
collection | PubMed |
description | N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is a well‐established biomarker in heart failure (HF) but controversially discussed as a potential surrogate marker in HF trials. We analyzed the NT‐proBNP/mortality relationship in real‐world data (RWD) of 108,330 HF patients from the IBM Watson Health Explorys database and compared it with the NT‐proBNP / clinical event end‐point relationship in 20 clinical HF studies. With a hierarchical statistical model, we quantified the functional relationship and interstudy variability. To independently qualify the model, we predicted outcome hazard ratios in five phase III HF studies solely based on NT‐proBNP measured early in the respective study. In RWD and clinical studies, the relationship between NT‐proBNP and clinical outcome is well described by an E(max) model. The NT‐proBNP independent baseline risk (R(0), RWD/studies median (interstudy interquartile range): 5.5%/3.0% (1.7–4.9%)) is very low compared with the potential NT‐proBNP–associated maximum risk (R(max): 55.2%/79.4% (61.5–89.0%)). The NT‐proBNP concentration associated with the half‐maximal risk is comparable in RWD and across clinical studies (EC(50): 3,880/2,414 pg/mL (1,460–4,355 pg/mL)). Model‐based predictions of phase III outcomes, relying on short‐term NT‐proBNP data only, match final trial results with comparable confidence intervals. Our analysis qualifies NT‐proBNP as a surrogate for clinical outcome in HF trials. NT‐proBNP levels after short treatment durations of less than 10 weeks quantitatively predict hazard ratios with confidence levels comparable to final trial readout. Early NT‐proBNP measurement can therefore enable shorter and smaller but still reliable HF trials. |
format | Online Article Text |
id | pubmed-8360001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83600012021-08-17 NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure Schmitt, Walter Rühs, Hauke Burghaus, Rolf Diedrich, Christian Duwal, Sulav Eissing, Thomas Garmann, Dirk Meyer, Michaela Ploeger, Bart Lippert, Jörg Clin Pharmacol Ther Research N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is a well‐established biomarker in heart failure (HF) but controversially discussed as a potential surrogate marker in HF trials. We analyzed the NT‐proBNP/mortality relationship in real‐world data (RWD) of 108,330 HF patients from the IBM Watson Health Explorys database and compared it with the NT‐proBNP / clinical event end‐point relationship in 20 clinical HF studies. With a hierarchical statistical model, we quantified the functional relationship and interstudy variability. To independently qualify the model, we predicted outcome hazard ratios in five phase III HF studies solely based on NT‐proBNP measured early in the respective study. In RWD and clinical studies, the relationship between NT‐proBNP and clinical outcome is well described by an E(max) model. The NT‐proBNP independent baseline risk (R(0), RWD/studies median (interstudy interquartile range): 5.5%/3.0% (1.7–4.9%)) is very low compared with the potential NT‐proBNP–associated maximum risk (R(max): 55.2%/79.4% (61.5–89.0%)). The NT‐proBNP concentration associated with the half‐maximal risk is comparable in RWD and across clinical studies (EC(50): 3,880/2,414 pg/mL (1,460–4,355 pg/mL)). Model‐based predictions of phase III outcomes, relying on short‐term NT‐proBNP data only, match final trial results with comparable confidence intervals. Our analysis qualifies NT‐proBNP as a surrogate for clinical outcome in HF trials. NT‐proBNP levels after short treatment durations of less than 10 weeks quantitatively predict hazard ratios with confidence levels comparable to final trial readout. Early NT‐proBNP measurement can therefore enable shorter and smaller but still reliable HF trials. John Wiley and Sons Inc. 2021-03-27 2021-08 /pmc/articles/PMC8360001/ /pubmed/33630302 http://dx.doi.org/10.1002/cpt.2222 Text en © 2021 Bayer AG. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Schmitt, Walter Rühs, Hauke Burghaus, Rolf Diedrich, Christian Duwal, Sulav Eissing, Thomas Garmann, Dirk Meyer, Michaela Ploeger, Bart Lippert, Jörg NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure |
title | NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure |
title_full | NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure |
title_fullStr | NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure |
title_full_unstemmed | NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure |
title_short | NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure |
title_sort | nt‐probnp qualifies as a surrogate for clinical end points in heart failure |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360001/ https://www.ncbi.nlm.nih.gov/pubmed/33630302 http://dx.doi.org/10.1002/cpt.2222 |
work_keys_str_mv | AT schmittwalter ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT ruhshauke ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT burghausrolf ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT diedrichchristian ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT duwalsulav ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT eissingthomas ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT garmanndirk ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT meyermichaela ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT ploegerbart ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure AT lippertjorg ntprobnpqualifiesasasurrogateforclinicalendpointsinheartfailure |